Population pharmacokinetics and exposure‐response of osimertinib in patients with non‐small cell lung cancer

Abstract

PopPK and exposure-response models were developed for osimertinib and AZ5104. There was no relationship between exposure and efficacy but a linear relationship between exposure and safety endpoints (rash, diarrhoea and QTcF) was observed.